1
|
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
|
Lancet
|
2010
|
5.59
|
2
|
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.
|
Blood
|
2005
|
2.06
|
3
|
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
|
Blood
|
2003
|
2.00
|
4
|
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
|
J Clin Oncol
|
2007
|
1.94
|
5
|
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
|
Haematologica
|
2002
|
1.47
|
6
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
7
|
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
|
J Clin Oncol
|
2011
|
1.32
|
8
|
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
|
Blood
|
2002
|
1.15
|
9
|
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
|
Eur J Haematol
|
2006
|
0.99
|
10
|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
|
Blood
|
2006
|
0.98
|
11
|
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
|
Br J Haematol
|
2007
|
0.94
|
12
|
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma.
|
Eur J Haematol
|
2005
|
0.91
|
13
|
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
|
Haematologica
|
2002
|
0.87
|
14
|
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
|
Eur J Haematol
|
2004
|
0.85
|
15
|
Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination.
|
Br J Haematol
|
2003
|
0.84
|
16
|
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.
|
J Clin Oncol
|
2006
|
0.83
|
17
|
Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
|
Haematologica
|
2002
|
0.82
|
18
|
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.
|
Mediterr J Hematol Infect Dis
|
2013
|
0.80
|
19
|
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization.
|
Blood
|
2003
|
0.77
|
20
|
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
|
Leuk Lymphoma
|
2004
|
0.77
|